首页 | 本学科首页   官方微博 | 高级检索  
     


Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences
Affiliation:1. Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;2. Thoracic & GU Oncology Unit Department of Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy;3. Pulmonary and Thoracic Oncology, CHU de Lille, Univ Lille, Mesoclin Network, F59000 Lille, France;4. Erasmus MC Cancer Institute, Rotterdam, The Netherlands;1. Section of Vascular Surgery and Endovascular Therapy, Department of Surgery, University of Colorado Denver, Aurora, CO;2. Department of Radiology, Presbyterian/St. Luke’s Medical Center, Denver, CO;3. Department of Radiology, Diversified Radiology of Colorado, Lakewood, CO;1. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA;2. Department of Urological Organ Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China;3. Division of Nephrology, University of California, San Diego, San Diego, California, USA;4. Department of Nephrology, University of California, Los Angeles, Los Angeles, California, USA
Abstract:Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types.Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.
Keywords:Mesothelioma  Immune-checkpoint  Immunotherapy  CTLA-4  PD-1  PD-L1
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号